Sponsored · Webinar
Aug. 19 – Next-Generation Drug Discovery: Leveraging E3 Ligases for Targeted Protein Degradation
The Next Dimension of Precision Medicine?
While you missed the live webinar, you can still watch a recording by following the link below.
E3 ligases have emerged as pivotal targets for drug discovery using the promising new paradigm of targeted protein degradation. This new paradigm includes both ligand binding-directed “reprogramming” of E3 substrate specificity approaches and a more directed approach, using small molecule proteolysis-targeting chimeras (PROTACs), to selectively degrade disease-driving proteins. As there are hundreds of diverse putative E3 ligases with differentiated tissue expression, this new paradigm may well define a next dimension of precision medicine defined by an axis of tissue-specific activity.
- The development and validation of the E3scan platform
- Our robust & high throughput assay library
- Correct control inhibitors testing
- Tight binding limits
- Assays that can support screening and SAR campaigns
Date: Wednesday, Aug. 19, 2020
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
Featuring: Ksenya Cohen Katsenelson – R&D Group Leader, Eurofins Discovery